Upadacitinib - AbbVie
Alternative Names: ABT-494; RINVOQ; RINVOQ LQ; Upadacitinib extended release - Abbvie; Upadacitinib modified release - Abbvie; Upadacitinib prolonged release - Abbvie; Upadacitinib tartrate; Upadicitinib hemihydrate - AbbvieLatest Information Update: 18 Jul 2024
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ankylosing spondylitis; Atopic dermatitis; Crohn's disease; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Registered Non-radiographic axial spondyloarthritis
- Preregistration Giant cell arteritis
- Phase III Alopecia areata; Hidradenitis suppurativa; Systemic lupus erythematosus; Vasculitis; Vitiligo
Most Recent Events
- 12 Jul 2024 Preregistration for Giant cell arteritis (Combination therapy, Treatment-experienced) in European Union (PO)
- 12 Jul 2024 Preregistration for Giant cell arteritis (Combination therapy, Treatment-experienced) in USA (PO)
- 17 Jun 2024 AbbVie plans a phase III Start Up trial for Atopic dermatitis (In children, Treatment-experience) in July 2024 (PO) (NCT06461897)